The Melanoma Drug the FDA Rejected Twice Just Got Approved
The FDA rejected Replimune's melanoma drug twice in nine months, calling the data uninterpretable. Then, on August 6th, they approved it. The two-year regulatory comeback is one of biotech's wildest recent stories.
Most drugs that get rejected by the FDA once don't come back. Getting rejected twice? That's usually a death sentence. So when Replimune's oncolytic virus therapy Tudriqev waltzed through the FDA's doors on August 6th with an accelerated approval, it wasn't just a win. It was one of the more remarkable comeback stories in recent biotech memory.
The drug, technically called vusolimogene oderparepvec (let's stick with Tudriqev), is now approved in combination with nivolumab for adults with advanced skin melanoma that has stopped responding to PD-1 blockers, which are the backbone of modern melanoma treatment. For patients who've run out of standard options, this is a genuinely new path.
But the real story isn't the approval itself. It's the two-year regulatory gauntlet Replimune survived to get here.
Two Strikes, Nearly Out
The FDA first rejected Tudriqev on July 22, 2025. The agency issued what's called a Complete Response Letter (CRL), which is essentially a formal "no, and here's why." The reasons were pointed: the pivotal trial, called IGNYTE, couldn't be reliably interpreted. The patient population was too varied, the FDA said, and the single-arm design made it hard to tell whether Tudriqev was actually pulling its weight alongside nivolumab.
Notably, the FDA didn't flag any safety problems. The issue was purely about evidence. Think of it like a student who got the right answer on a math test but didn't show enough work. The teacher isn't buying it.
Replimune regrouped, added new analyses, and resubmitted by October 2025. Then, on April 10, 2026, the FDA rejected them again. Same core objection: the data still didn't prove Tudriqev's contribution clearly enough. The agency also poked holes in a new Phase 3 study Replimune had tacked onto the resubmission, noting it had enrolled only a fraction of its planned patients and produced hard-to-interpret progression-free survival data.
Two CRLs in nine months. Most companies would've shelved the program and moved on.
So What Changed?
This is where the story gets interesting. Between the second rejection in April and the approval in August, the FDA convened an advisory committee to take a closer look at the IGNYTE data. That panel voted that the results were
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
"evaluable and clinically meaningful."
That's a significant shift. The same data the FDA had twice called insufficient was now, through the lens of an expert committee, deemed worthy. It's a bit like a restaurant getting two bad Yelp reviews, then having a Michelin inspector show up and hand them a star.
The approval came through the accelerated pathway, which means it's based on a surrogate measure (in this case, response rate and how long responses lasted) rather than proof that patients live longer. Replimune will need to run confirmatory studies to keep the approval. Specifically, the FDA wants a trial in patients who've progressed on both anti-PD-1 and anti-CTLA-4 therapies. If those studies disappoint, the approval can be pulled. That's not a hypothetical threat: the FDA has withdrawn accelerated approvals for drugs like bevacizumab in breast cancer and, more recently, tazemetostat in 2026.
The Data That (Eventually) Won
The IGNYTE trial enrolled 140 patients with advanced melanoma that had stopped responding to anti-PD-1 therapy. In the efficacy-evaluable group of 91 patients (those with at least one tumor that wasn't directly injected), the overall response rate was 24.2% with a median duration of response of 14.1 months.
Looking at the broader published cohort, the numbers were stronger: a 33.6% response rate, a 16.4% complete response rate, and a median duration of response stretching to 24.8 months. Median overall survival across all treated patients hit 32.9 months, and responders had a striking three-year survival rate of 83.5%.
Those response numbers might sound modest if you're used to hearing about 90%-effective vaccines. But for patients whose cancer has already shrugged off the best immunotherapy available, a roughly one-in-three chance of responding (with some responses lasting nearly three years) is meaningful. Especially when survival data shows nearly half of all treated patients were alive at three years.
Critically, responses showed up in both injected and non-injected tumors, including visceral lesions. That matters because it suggests the therapy isn't just working locally; it's priming the immune system to hunt cancer elsewhere in the body.
What Exactly Is an Oncolytic Virus?
Tudriqev belongs to a class of therapies called oncolytic viruses: engineered viruses that are designed to infect and kill cancer cells while leaving healthy tissue alone. Think of it as a biological Trojan horse. The virus gets injected directly into a tumor, replicates inside cancer cells, and blows them up. As the cells die, they spill their contents, which essentially waves a giant flag for the immune system to come attack.
Pairing an oncolytic virus with nivolumab (a checkpoint inhibitor that takes the brakes off the immune system) is the combination logic here. One agent sounds the alarm; the other makes sure the immune system actually responds.
The only other oncolytic virus with a real track record in melanoma is T-VEC (Imlygic), approved years ago. But T-VEC is mainly a local therapy; it works best on injectable tumors and doesn't control distant disease well. Tudriqev's ability to trigger responses in non-injected, visceral lesions is what sets it apart, at least based on the IGNYTE data.
Wall Street: Cautiously Optimistic (With Emphasis on "Cautiously")
Analyst reactions have been all over the map. JPMorgan maintained an Overweight rating and bumped its price target from $17 to $20. Piper Sandler and BMO Capital both rate Replimune a Buy. Wedbush upgraded to Outperform.
But the consensus is still a Hold. Average price targets range from under $5 on the bearish end to $20 on the bull case, which is an enormous spread. It signals that Wall Street sees the approval as necessary but not sufficient. The real question is commercial execution: can Replimune actually launch this drug, price it competitively, and build a sales operation from scratch?
That's a legitimate concern. Replimune is a small company going up against entrenched melanoma franchises. Approval is the starting line, not the finish.
The Bigger Picture
Tudriqev's approval matters beyond Replimune's stock ticker. It validates an entire class of therapy that has struggled to break through. The oncolytic virus pipeline is crowded with candidates from companies like Candel Therapeutics, Oncolytics Biotech, Imugene, and Transgene, all chasing the same basic idea: weaponize viruses against cancer. A high-profile FDA approval, even one that took three tries, gives the whole field a credibility boost.
More broadly, this is a story about what happens when a biotech company refuses to quit. Two rejections, mounting skepticism, a shrinking stock price. Replimune kept going back, kept refining the case, and eventually convinced the FDA to see the data differently.
That persistence doesn't always pay off. Sometimes a drug really is a dead end. But every now and then, the third time actually is the charm.
4 min read
The Gene Editor That Might Actually Delete Hepatitis B
Precision BioSciences just showed the first clinical evidence that a gene editor can destroy cccDNA, the hidden viral reservoir that makes hepatitis B nearly impossible to cure. If it holds up, 250 million patients worldwide could finally have a path off lifelong medication.
